Prothena Co. plc (NASDAQ:PRTA) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lessened its holdings in Prothena Co. plc (NASDAQ:PRTAFree Report) by 21.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 867,635 shares of the biotechnology company’s stock after selling 235,227 shares during the quarter. Dimensional Fund Advisors LP owned 1.62% of Prothena worth $31,533,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Headlands Technologies LLC acquired a new stake in Prothena in the 3rd quarter worth approximately $74,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Prothena by 351.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,203 shares of the biotechnology company’s stock worth $225,000 after buying an additional 4,828 shares during the period. HealthInvest Partners AB purchased a new stake in shares of Prothena during the fourth quarter valued at $303,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Prothena by 28.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,563 shares of the biotechnology company’s stock valued at $348,000 after acquiring an additional 2,099 shares during the period. Finally, Oppenheimer & Co. Inc. raised its stake in Prothena by 3.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 7,908 shares of the biotechnology company’s stock worth $382,000 after acquiring an additional 295 shares during the last quarter. Hedge funds and other institutional investors own 97.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PRTA. HC Wainwright cut their price objective on Prothena from $90.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Royal Bank of Canada dropped their price objective on shares of Prothena from $36.00 to $35.00 and set a “sector perform” rating on the stock in a report on Friday, February 16th. JMP Securities reduced their target price on shares of Prothena from $85.00 to $83.00 and set a “market outperform” rating for the company in a report on Thursday, May 9th. StockNews.com downgraded shares of Prothena from a “hold” rating to a “sell” rating in a research report on Monday, February 19th. Finally, Oppenheimer reduced their price objective on Prothena from $98.00 to $80.00 and set an “outperform” rating for the company in a research note on Tuesday, February 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $67.00.

Get Our Latest Report on Prothena

Prothena Trading Up 3.0 %

Shares of Prothena stock opened at $20.81 on Friday. The firm has a 50-day simple moving average of $22.19 and a two-hundred day simple moving average of $28.71. Prothena Co. plc has a fifty-two week low of $19.52 and a fifty-two week high of $77.13.

Prothena (NASDAQ:PRTAGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.13). Prothena had a negative return on equity of 30.48% and a negative net margin of 193.17%. The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $3.75 million. During the same period in the previous year, the company posted ($0.89) EPS. On average, equities research analysts forecast that Prothena Co. plc will post -4.69 earnings per share for the current year.

About Prothena

(Free Report)

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

Featured Stories

Institutional Ownership by Quarter for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.